Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy

This study tests whether a diabetes medication called dapagliflozin (an SGLT2 inhibitor) can protect the heart from damage caused by anthracycline-based chemotherapy (a common breast cancer treatment known to affect heart function). **You may be eligible if...** - You are a woman over 18 years old with breast cancer - You are scheduled to receive anthracycline chemotherapy (equivalent to at least 240 mg/m² of doxorubicin) **You may NOT be eligible if...** - You have a pacemaker, defibrillator, certain metal implants, or cochlear implant (which would prevent MRI scans) - You have claustrophobia that prevents MRI - You have severe kidney disease (very low filtration rate) - You have a history of heart attack, heart failure, heart surgery, or significant heart valve or muscle disease Talk to your doctor to see if this trial is right for you.